ANVISA scABEL - sample size [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2015-06-05 13:03 (3571 d 20:12 ago) – Posting: # 14916
Views: 9,430

Dear Helmut! Dear All!

Proud to announce:
PowerTOST V1.2-07 is on CRAN now :cool:.
After fiddling with such ugly requests like "Title case".

First look on sample size:
Settings: design="2x3x3", theta0=0.9 (acc. to the two Laszlo's), targetpower=0.8

CV     N(EMA) N(ANVISA)
-----------------------
0.25      42       42
0.275     48       51
0.3       54       60
0.325     51       69
0.35      48       78
0.375     45       78
0.4       42       63
0.425     42       51
0.45      39       45
0.475     39       42
0.5       39       42
0.525     42       42
0.55      42       42
0.575     45       45
0.6       48       48
0.65      54       54
0.7       60       60
0.8       75       75


As you see there is a partly considerable rise in burden for the ANVISA settings compared to the EMA in the range CV=30 - 45%(!). In this range ANVISA is actually more conservative than EMA. Note the range CV=40-45% where the widened acceptance ranges are identical for both regulatory settings but sample size is higher for ANVISA.

After reaching the CV where a cap has to be placed on the widening (CV=50%) of the acceptance range both regulatory settings give the same sample size needed.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,667 registered users;
62 visitors (0 registered, 62 guests [including 10 identified bots]).
Forum time: 08:16 CET (Europe/Vienna)

They must find it difficult…; those who have taken authority as the truth,
rather than truth as the authority.    Gerald Massey

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5